A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE networkArticle Published on 2022-10-082022-11-15 Journal: Trials [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ≥75 years. adaptive addition advanced age age Analysis Antibody titre benefit BNT162b2 BNT162b2 (Comirnaty®) booster booster dose changes in Clinical course collected concern conducted COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine dose Endpoint enzyme-linked immunosorbent evaluate exploratory fourth dose humoral immune response immunosenescence include individual initial Intervention mRNA-1273 mRNA-1273 (Spikevax®) multicentre neutralising neutralising antibody titre Older Part Patient performed phase phase II primary endpoint protocol qPCR Quantitative randomisation randomised randomised controlled reactogenicity Research risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine secondary subgroup T cell response the primary endpoint Trial triggered vaccination Vaccine vaccine-induced immune response variants variants of concern VoC wild-type wild-type virus [DOI] 10.1186/s13063-022-06791-y PMC 바로가기
Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variantArticle Published on 2022-10-012022-11-15 Journal: The Journal of heart and lung transplantation : th [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] accelerate applied BNT162b2 BNT162b2 vaccine Bonferroni method cellular continuous variable COVID-19 vaccine declined dichotomous variables dose effective elicited geometric mean titer GMT Heart transplantation Humoral response immune response implication Kinetics Kruskal-Wallis test mRNA vaccines neutralization Neutralizing Neutralizing activity Omicron variant Omicron. percentage recipient remained SARS-CoV-2-specificT-cell sera serum sustained T-cell Response transmissible variant vaccination variant wild-type wild-type virus [DOI] 10.1016/j.healun.2022.05.014 PMC 바로가기
Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinationsArticle Published on 2022-09-022022-11-16 Journal: Communications Biology [Category] SARS, 변종, [키워드] antibody Antibody Response booster dose Course COVID-19 COVID-19 patient cross-protection delta variant drastic reduction elicited ENhance evaluate Heterologous highest homologous Immunity mRNA vaccine Mutation natural infection neutralization capacity neutralize omicron Patient regimen replaced SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 virus serum sample survivor susceptibility tested the spike protein vaccinated individual vaccination Vaccine vaccinee variant wild-type virus [DOI] 10.1038/s42003-022-03849-0 PMC 바로가기
Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantationArticle Published on 2022-09-012022-11-15 Journal: The Journal of heart and lung transplantation : th [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] Anti-RBD antibody anti-RBD IgG antibody Antibody Response BNT162b2 BNT162b2 vaccine cellular immunity changes in Delta variants demonstrated detectable domain dose Efficacy Efficiency elicit fourth dose group Heart transplantation high-risk population IgG immune responses Immunological response IMPROVE Infection investigated long-lasting majority neutralization neutralizing antibody neutralizing responses omicron Omicron variant preventive measure recipients vaccination Vaccination strategy variant variants of concern variants of concern. wild-type virus [DOI] 10.1016/j.healun.2022.04.014 PMC 바로가기
Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tractArticle Published on 2022-09-012022-11-16 Journal: EBioMedicine [Category] SARS, 변종, [키워드] airway antibody bronchial Bronchial tissue characterized China clinical manifestation Committee comparable Culture Delta delta variant disease severity Ex vivo explain explained Hong Kong human lung tissue immune evasion Infectious disease Lower respiratory tract lung lung tissue nasal nasal tissue observation omicron Omicron BA.2 parenchymal pathogenicity Patient Region replaced replicated Replication respiratory tissue SARS-CoV-2 strain Strains supported tested tissue Transmissibility Transmission. university variant virus viruses wild-type wild-type virus [DOI] 10.1016/j.ebiom.2022.104232 PMC 바로가기
Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or VaccinationArticle Published on 2022-08-312022-11-15 Journal: Journal of Immunology Research [Category] SARS, 변종, 진단, [키워드] adenovirus-based antibody Antibody avidity avidity bind binding binding antibody cellular receptor collected cross-protection domain dose elicited epitope exhibit Heterologous high affinity Immunity increase mRNA vaccine Mutation natural infection Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody Neutralizing titer omicron pandemic patients Protective antibody RBD RBD-binding IgG remained response Sample SARS-CoV-2 SARS-CoV-2 infected patient SARS-CoV-2 spike protein subject tested the RBD the spike protein vaccination Vaccine vaccine dose vaccinees Vaccines variant virus wild-type wild-type SARS-CoV-2 wild-type virus [DOI] 10.1155/2022/4813199 PMC 바로가기
Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccinemRNA 백신 3회 투여 후 이식 수혜자에서 Omicron 변이체에 대한 중화Article Published on 2022-08-012022-09-11 Journal: American journal of transplantation : official jou [Category] MERS, SARS, 변종, 진단, 치료기술, [키워드] analyzed anti-RBD circulating completion COVID-19 vaccine Delta demographic variable Demographic variables detectable dominant dose heart immunogenicity Infection infection and infectious agents-viral: SARS-CoV-2/COVID-19 infectious agents Infectious disease kidney lentivirus liver log lung median mRNA mRNA vaccine mRNA vaccines mRNA-1273 mRNA-1273 vaccine neutralization neutralizing antibody Neutralizing antibody response neutralizing response omicron Omicron variant Patient patients positive positive patient positive patients proportion pseudotyped recipient reduction SARS-CoV-2 spike SARS-CoV-2 virus significantly translational translational research/science undetectable Vaccine vaccine. variant variants was determined wild-type wild-type virus [DOI] 10.1111/ajt.17020 PMC 바로가기 [Article Type] Article
The ongoing effects of the COVID-19 pandemic on perceived physical activity, physical function and mood of older adults in the U.K: A follow-up study (March 2020-June 2021)COVID-19 대유행이 영국 노인의 인지된 신체 활동, 신체 기능 및 기분에 미치는 지속적인 영향: 후속 연구(2020년 3월-2021년 6월)Observational Study Published on 2022-08-012022-09-11 Journal: Experimental gerontology [Category] 변종, 임상, [키워드] Bayesian analysis calculation clinically conducted COVID-19 COVID-19 pandemic decrease Effect effort female Follow-up follow-up study impacted intensity interval knowledge male margin MONITOR mood observational study Older older adult Older adults participant pattern physical physical activity physical activity level physical activity levels physical activity. Probability reflected Spread United Kingdom variants wild-type virus Wuhan Wuhan, China [DOI] 10.1016/j.exger.2022.111838 PMC 바로가기 [Article Type] Observational Study
A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions액세서리 단백질이 결실된 생약독화 SARS-CoV-2 백신 후보Article Published on 2022-07-272022-09-11 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, 치료제, [키워드] Antiviral approved biosafety cultures deleted Deletion hamster hamsters immunization interferon interferon signaling K18-hACE2 live-attenuated vaccine mNeonGreen Mouse models neutralization ORF ORF3a ORFs Phosphorylation primary human airway PROTECT Protein replicate Replication reporter Research SARS-CoV-2 SARS-CoV-2 vaccine sequence Stat1 Transmission vaccine production Vero-E6 cell Viral viral transcription virus wild-type SARS-CoV-2 wild-type virus [DOI] 10.1038/s41467-022-31930-z PMC 바로가기 [Article Type] Article
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trialArticle Published on 2022-07-222022-10-06 Journal: EClinicalMedicine [Category] 진단, [키워드] adverse event adverse events anti-SARS-CoV-2 approach AS03 cellular immunity CEPI clinical study conducted COVID-19 COVID-19 pandemic deviation displaying distribution dose eligible Emergency use enrolled evaluate evaluated flu vaccine foundation geometric mean concentration group groups healthy hospital Humoral immunity IgG antibody immunogenic immunogenicity injection site pain Intervention intramuscularly Investment Local Melinda Gate mitigate myalgia naïve nanoparticle nanoparticle vaccine neutralizing antibody observer-blinded outcome participant per-protocol phase Placebo placebo-controlled primary immunogenicity Protein protocol pseudovirus randomised RBD RBD IgG reached reactogenicity receive recipient Recombinant protein recombinant protein vaccine Registered reported Safety SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2. second dose Stage study enrollment Support supported systemic AE systemic AEs T-cell immune responses the receptor-binding domain the vaccine titre Trial vaccination vaccination schedule Vaccine wild-type virus World Health Organization [DOI] 10.1016/j.eclinm.2022.101569 PMC 바로가기 [Article Type] Article